Tweet
Boston Partners boosted its stake in Abbott Laboratories (NYSE:ABT) by 9.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,542,151 shares of the healthcare product maker's stock after purchasing an additional 213,732 shares during the period. Boston Partners owned about 0.15% of Abbott Laboratories worth $155,046,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of ABT. BlackRock Inc. increased its holdings in Abbott Laboratories by 1.6% in the first quarter. BlackRock Inc. now owns 111,996,583 shares of the healthcare product maker's stock valued at $6,710,836,000 after purchasing an additional 1,795,199 shares during the period. Swedbank acquired a new stake in Abbott Laboratories during the 2nd quarter worth about $101,535,000. Montag & Caldwell LLC acquired a new stake in Abbott Laboratories during the 1st quarter worth about $97,503,000. Ceredex Value Advisors LLC acquired a new stake in Abbott Laboratories during the 1st quarter worth about $97,236,000. Finally, Cornerstone Wealth Management LLC grew its holdings in Abbott Laboratories by 6,017.4% during the 2nd quarter. Cornerstone Wealth Management LLC now owns 960,183 shares of the healthcare product maker's stock worth $15,739,000 after acquiring an additional 944,487 shares during the period. Institutional investors and hedge funds own 71.80% of the company's stock. Get Abbott Laboratories alerts:
Shares of ABT opened at $64.16 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.58 and a quick ratio of 1.16. The stock has a market capitalization of $112.33 billion, a PE ratio of 25.66, a PEG ratio of 1.79 and a beta of 1.53. Abbott Laboratories has a one year low of $48.58 and a one year high of $65.90. Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, July 18th. The healthcare product maker reported $0.73 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.71 by $0.02. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.71 billion. Abbott Laboratories had a return on equity of 15.30% and a net margin of 3.13%. The firm's revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period last year, the business posted $0.62 EPS. sell-side analysts forecast that Abbott Laboratories will post 2.88 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, August 15th. Stockholders of record on Friday, July 13th were paid a $0.28 dividend. The ex-dividend date was Thursday, July 12th. This represents a $1.12 annualized dividend and a dividend yield of 1.75%. Abbott Laboratories's dividend payout ratio is presently 44.80%.
A number of analysts have weighed in on the company. Zacks Investment Research downgraded Abbott Laboratories from a "buy" rating to a "hold" rating in a report on Tuesday, July 31st. Citigroup decreased their price target on Abbott Laboratories from $66.00 to $65.00 and set a "neutral" rating for the company in a report on Tuesday, April 24th. Sanford C. Bernstein assumed coverage on Abbott Laboratories in a report on Wednesday, June 27th. They set an "outperform" rating and a $73.00 price target for the company. BTIG Research reiterated a "hold" rating on shares of Abbott Laboratories in a report on Sunday, April 22nd. Finally, Royal Bank of Canada reiterated a "buy" rating and set a $70.00 price target on shares of Abbott Laboratories in a report on Thursday, July 19th. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock has a consensus rating of "Buy" and an average price target of $69.88.
In other news, insider Michael J. Pederson sold 1,050 shares of the firm's stock in a transaction dated Tuesday, July 24th. The stock was sold at an average price of $63.43, for a total value of $66,601.50. Following the completion of the sale, the insider now directly owns 79,467 shares in the company, valued at approximately $5,040,591.81. The sale was disclosed in a document filed with the SEC, which is accessible through this link . Also, EVP Brian J. Blaser sold 15,100 shares of the firm's stock in a transaction dated Tuesday, July 24th. The shares were sold at an average price of $63.96, for a total value of $965,796.00. Following the completion of the sale, the executive vice president now owns 151,718 shares of the company's stock, valued at $9,703,883.28. The disclosure for this sale can be found here . Over the last 90 days, insiders sold 17,024 shares of company stock valued at $1,088,840. 0.74% of the stock is currently owned by company insiders.
Abbott Laboratories Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; MÃ©niÃ¨re's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon